Last reviewed · How we verify
Fludarabine , cytarabine
Fludarabine is a nucleoside analog that inhibits DNA synthesis by interfering with ribonucleotide reductase.
Fludarabine is a nucleoside analog that inhibits DNA synthesis by interfering with ribonucleotide reductase. Used for Chronic lymphocytic leukemia, Non-Hodgkin's lymphoma.
At a glance
| Generic name | Fludarabine , cytarabine |
|---|---|
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fludarabine works by inhibiting the enzyme ribonucleotide reductase, which is necessary for DNA synthesis. This leads to the inhibition of DNA synthesis and cell death in rapidly dividing cells, such as cancer cells.
Approved indications
- Chronic lymphocytic leukemia
- Non-Hodgkin's lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PHASE2)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NA)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludarabine , cytarabine CI brief — competitive landscape report
- Fludarabine , cytarabine updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI